Gilead Sciences Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
What’s Fueling Gilead Sciences Inc (GILD) Stock’s 17.82% Gain Above Its 200-Day SMA?
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and touched a low of $92.
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of
Gilead Sciences Inc (GILD)’s Stock Surge: What You Need to Know
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and touched a low of $91.
Cognizant expands AI services for Gilead Sciences
Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,201.60 today based on a ...
Yahoo Finance4d
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
The HIV and hepatitis C drugmaker's stock has climbed by 3.63% in the ... Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure.
Investing3d
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical ... As of Wednesday, January 29, 2025, the company's stock outlook is being shaped by recent developments in its product ...
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...